계명대학교 의학도서관 Repository

Real World Experience of Nivolumab in Non-Small Cell Lung Cancer in Korea

Metadata Downloads
Author(s)
Sun Min LimSang-We KimByoung Chul ChoJin Hyung KangMyung-Ju AhnDong-Wan KimYoung-Chul KimJin Soo LeeJong-Seok LeeSung Yong LeeKeon Uk ParkHo Jung AnEun Kyung ChoTae Won JangBong-Seog KimJoo-Hang KimSung Sook LeeIm-II NaSeung Soo YooKi Hyeong Lee
Keimyung Author(s)
Park, Keon Uk
Department
Dept. of Internal Medicine (내과학)
Journal Title
Cancer Research and Treatment
Issued Date
2020
Volume
52
Issue
4
Keyword
Non-small cell lung cancerAnti–PD-1Real-world data
Abstract
Purpose:
The introduction of immune checkpoint inhibitors represents a major advance in the treatment of lung cancer, allowing sustained recovery in a significant proportion of patients. Nivolumab is a monoclonal anti–programmed death cell protein 1 antibody licensed for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy. In this study, we describe the demographic and clinical outcomes of patients with advanced NSCLC treated with nivolumab in the Korean expanded access program.

Materials and Methods:
Previously treated patients with advanced non-squamous and squamous NSCLC patients received nivolumab at 3 mg/kg every 2 weeks up to 36 months. Efficacy data including investigator-assessed tumor response, progression data, survival, and safety data were collected.

Results:
Two hundred ninety-nine patients were treated across 36 Korean centers. The objective response rate and disease control rate were 18% and 49%, respectively; the median progression-free survival was 2.1 months (95% confidence interval [CI], 1.87 to 3.45), and the overall survival (OS) was 13.2 months (95% CI, 10.6 to 18.9). Patients with smoking history and patients who experienced immune-related adverse events showed a prolonged OS. Cox regression analysis identified smoking history, presence of immune-related adverse events as positive factors associated with OS, while liver metastasis was a negative factor associated with OS. The safety profile was generally comparable to previously reported data.

Conclusion:
This real-world analysis supports the use of nivolumab for pretreated NSCLC patients, including those with an older age.
Keimyung Author(s)(Kor)
박건욱
Publisher
School of Medicine (의과대학)
Citation
Sun Min Lim et al. (2020). Real World Experience of Nivolumab in Non-Small Cell Lung Cancer in Korea. Cancer Research and Treatment, 52(4), 1112–1119. doi: 10.4143/crt.2020.245
Type
Article
ISSN
2005-9256
Source
https://www.e-crt.org/journal/view.php?number=3099
DOI
10.4143/crt.2020.245
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/42830
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Internal Medicine (내과학)
공개 및 라이선스
  • 공개 구분공개
파일 목록

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.